Skip to content

Study · Case report or series · n = 6 · 2015

5 results

Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: A case series.

Cariou B, Bernard C, Cantarovich D

Diabetes & metabolism4 Nov 2014Cited by 15 (Europe PMC)

PMID25457472 (opens in a new tab)DOI10.1016/j.diabet.2014.10.004 (opens in a new tab)PepBankPUB-25457472
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In six recipients of a whole-pancreas transplant with type 1 diabetes, gastrointestinal disorders occurred in three patients on liraglutide.

    In plain wordsIn six pancreas transplant recipients with type 1 diabetes, three had stomach or gut problems on liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableGastrointestinal disorders
    Study

    n = 6

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.6 mg once daily titrated to 1.2 mg once daily at week 1 · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Gastrointestinal disorders were reported in three of the six patients, with discontinuation of liraglutide in only one patient.
    1 context sentence
    Summary · context
    This report is a 6-month prospective follow-up of six T1DM recipients of PTX (mean time after PTX: 68.8 ± 45.7 months), all of whom had an HbA1c>6.5% (48 mmol/mol) [mean: 7.1% (54 mmol/mol)] after initiation of liraglutide alone at 0.6 mg once daily titrated to 1.2mg once daily at week 1.
  2. 02HumanCase report or seriesSafety outcome

    In six recipients of a whole-pancreas transplant with type 1 diabetes, one patient stopped liraglutide.

    In plain wordsIn six pancreas transplant recipients with type 1 diabetes, one stopped taking liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableDiscontinuation of liraglutide
    Study

    n = 6

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.6 mg once daily titrated to 1.2 mg once daily at week 1 · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    with discontinuation of liraglutide in only one patient.
    1 context sentence
    Summary · context
    This report is a 6-month prospective follow-up of six T1DM recipients of PTX (mean time after PTX: 68.8 ± 45.7 months), all of whom had an HbA1c>6.5% (48 mmol/mol) [mean: 7.1% (54 mmol/mol)] after initiation of liraglutide alone at 0.6 mg once daily titrated to 1.2mg once daily at week 1.
  3. 03HumanCase report or seriesSafety outcome

    In recipients of a whole-pancreas transplant with type 1 diabetes, immunosuppressive treatments remained unchanged with liraglutide.

    In plain wordsIn pancreas transplant recipients with type 1 diabetes, liraglutide did not lead to changes in immunosuppressive treatment.

    Peptide
    Liraglutide
    Outcome
    No significant changeImmunosuppressive treatment
    Study

    n = 6

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    0.6 mg once daily titrated to 1.2 mg once daily at week 1 · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Immunosuppressive treatments remained unchanged with liraglutide.
    1 context sentence
    Summary · context
    This report is a 6-month prospective follow-up of six T1DM recipients of PTX (mean time after PTX: 68.8 ± 45.7 months), all of whom had an HbA1c>6.5% (48 mmol/mol) [mean: 7.1% (54 mmol/mol)] after initiation of liraglutide alone at 0.6 mg once daily titrated to 1.2mg once daily at week 1.
  4. 04HumanCase report or seriesEfficacy outcome

    In five of six recipients of a whole-pancreas transplant with type 1 diabetes who stayed on liraglutide, HbA1c fell by a median of 0.8% at 6 months.

    In plain wordsIn pancreas transplant recipients with type 1 diabetes who stayed on liraglutide, HbA1c fell after 6 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change at 6 months
    Study

    n = 5

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.6 mg once daily titrated to 1.2 mg once daily at week 1 · 6 monthsAs given in this study (human).

    Measurements

    HbA1c median decrease
    0.8%
    at 6 months

    Source sentences

    Summary
    HbA1c improved in the five remaining patients, with a median decrease of 0.8% (0.0-2.7%) at 6 months
    1 context sentence
    Summary · context
    This report is a 6-month prospective follow-up of six T1DM recipients of PTX (mean time after PTX: 68.8 ± 45.7 months), all of whom had an HbA1c>6.5% (48 mmol/mol) [mean: 7.1% (54 mmol/mol)] after initiation of liraglutide alone at 0.6 mg once daily titrated to 1.2mg once daily at week 1.
  5. 05HumanCase report or seriesEfficacy outcome

    In recipients of a whole-pancreas transplant with type 1 diabetes on liraglutide, median body weight fell by 2.0 kg.

    In plain wordsIn pancreas transplant recipients with type 1 diabetes, body weight fell after liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change at 6 months
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.6 mg once daily titrated to 1.2 mg once daily at week 1 · 6 monthsAs given in this study (human).

    Measurements

    Body weight median decrease
    2 kg
    at 6 months

    Source sentences

    Summary
    the median decrease in body weight was 2.0 kg.
    1 context sentence
    Summary · context
    This report is a 6-month prospective follow-up of six T1DM recipients of PTX (mean time after PTX: 68.8 ± 45.7 months), all of whom had an HbA1c>6.5% (48 mmol/mol) [mean: 7.1% (54 mmol/mol)] after initiation of liraglutide alone at 0.6 mg once daily titrated to 1.2mg once daily at week 1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.